Business & Regulation Business Practice, Standards & Regulation, Trends & Forecasts

All Eyes on EMA Approvals

From anti-cancer viruses to H3 blocking narcolepsy drugs – we present a year in European drug approvals

02/09/2016

The European Medicines Agency (EMA) recently released its “highlights of 2015” in terms of new medicine approvals. All in all, it seems that 2015 was a good year with 93 medicines recommended for marketing authorization, including 39 new active substances. In 2014, on the other hand, just 82 new products were recommended for approval. Our infographic brings you up to speed with some of the key approvals from 2015 that will likely be coming to a European market near you soon.

Inspections were conducted in 62 countries worldwide

>2,590 GMP inspections. >270 GCP inspections.
>190 pharmacovigilance inspections.

Highlights:

Blincyto for patients with acute lymphoblastic leukemia
Farydak for patients with multiple myeloma
Hetlioz for blind adults with sleep-wake disorder
Kanuma for patients with lysosomal acid lipase deficiency
Kyprolis for patients with multiple myeloma
Lenvima for patients with thyroid cancer
Strensiq for patients with childhood hypophosphatasia
Unituxin for patients with brain cancer (neuroblastoma)

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.